PUBLIC COMPANY
save$OCULOCULAR THERAPEUTIX, INC
$OCUL6.9600-4.53%Bedford, MA, USupdated 17h ago
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
7
approvals ytd
1
recalls ytd
2
Pipeline(2)
pipeline depth2 products
1Phase 31Marketed
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase2A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- phase3Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
- phase3A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- phase3Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
- phase3Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
- phase1CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
- phase1CLN-0046: Treatment of AMD Subjects With OTX-TKI
- phase2OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Apr 9, 26giftDugel Pravin · See Remarks394,696 sh
- Apr 9, 26giftDugel Pravin · See Remarks394,696 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and moreEyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goalstat · 1mo ago
- STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promiseEyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.stat · 1mo ago
- EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD raceEyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.biospace · 1mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that